Please assess the completion status of the following clinical trial:

Trial Title: A Study To Determine Any Effect Of Tafamidis On Electrocardiographic Intervals, Specifically The Rate Corrected QT Interval (QTc)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy, nonsmoking, male and/or female subjects of non-childbearing potential.~* Body Mass Index (BMI) of 17.5 to 30.5 kg/m2.~* Total body weight \>50 kg (110 lbs).~Exclusion Criteria:~* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.~* An ALT or AST measurement \>2 times the ULN.~* 12-lead ECG demonstrating QTc \>450 msec or a QRS interval \>120 msec at Screening.~* Subjects at increased risk if dosed with moxifloxacin, according to the product label for moxifloxacin.~* History of risk factors of QT prolongation or torsades de pointes, congenital deafness and family history of sudden death.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Period 1: 960 mg tafamidis (Vyndaqel) (Type: EXPERIMENTAL): None
- Period 2: 400 mg moxifloxacin (Type: EXPERIMENTAL): 400 mg moxifloxacin
- Period 3: Placebo (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).